Innovative Drug Developer Simcere Reports Falling Profits; Negotiates With Government Over Inclusion In National Insurance Catalogue

BEIJING - Simcere Pharmaceutical Group posted lower-than-expected earnings for the third quarter of 2009 as the worldwide economic slowdown and limited health insurance coverage inside China hurt sales of the outfit's most innovative and expensive biopharmaceutical, according to Simcere's leadership